Implementation of american society of clinical oncology/college of american pathologists HER2 guideline recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 5, 2009, Pages 775-780

  Middleton, Lavinia P ^a   Price, Kathy M ^a   Puig, Pamela ^a   Heydon, Lori J ^a   Tarco, Emily ^a   Sneige, Nour ^a   Barr, Kaye ^a   Deavers, Michael T ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; TUMOR MARKER;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEALTH CARE QUALITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MEDICAL SOCIETY; NEEDLE BIOPSY; PRACTICE GUIDELINE; PROGNOSIS; STANDARDIZATION; TERTIARY HEALTH CARE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PROTO ONCOGENE; REPRODUCIBILITY; STANDARD;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GUIDELINES AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 65649135081     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuireWL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science. 1987;235(4785):1 77-182.
2. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(1 6):1972-1977.
3. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress- es HER2. N Engl J Med. 2001;344(11):783-792.
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. JClin Oncol. 1999;17(9):2639-2648.
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726.
7. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94(1 1):852-854.
8. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breastintergroup trial N9831. JNatlCancer Inst. 2002;94(1 1):855-857.
9. Wolf AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breastcancer. ArchPatholLab Med. 2007;131(1):18-43.
10. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver re- producibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113(6):852-859.
11. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120(1):86-92.
12. Benneyan JC, Lloyd RC, Plsek PE. Statistical process control as a tool for research and healthcare improvement. Qual Saf Health Care. 2003;12(6):458-464.
13. Lombardo JF. American Society ofClinical Oncology/CollegeofAmerican Pathologists guidelines should be scientifically validated. Arch Pathol Lab Med. 2007;131(10):1510.